fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

New research offers hope for preventing epilepsy after traumatic brain injury

Written by | 28 Jan 2025

A new international study has unveiled critical insights in understanding post-traumatic epilepsy (PTE), a condition that can develop following traumatic brain injury. Led by researchers at FutureNeuro, the… read more.

Newer epilepsy medications used during pregnancy do not affect neurological development in children

Written by | 4 Dec 2024

Children of mothers who took certain antiseizure medications while pregnant do not have worse neurodevelopmental outcomes at age 6, according to a long-running study funded by the National… read more.

UCB to accelerate innovation and strategic partnerships, divesting mature product portfolio in China to CBC Group.

Written by | 2 Sep 2024

UCB, a global biopharmaceutical company, announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets…. read more.

Antiseizure medications can produce life-threatening reactions

Written by | 24 Jun 2024

Targeted blood tests, asking patients about risk factors, and dose modifications can lessen the risk of potentially fatal reactions to antiseizure medications that millions of Americans take for… read more.

Global experts release new guidelines on prevention of progression of epileptic seizures, addressing critical treatment gaps – UCB

Written by | 17 Jun 2024

New recommendations released in Epileptic Disorders by a global expert group comprising epileptologists, neurologists and pharmacologists from Europe and North America address the critical unmet needs associated with… read more.

Fycompa (perampanel hydrate) is approved in China for adjunctive treatment of primary generalised tonic-clonic seizures – Eisai

Written by | 21 May 2024

Eisai announces approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic/clonic… read more.

New guidelines aim to elevate comprehensive care for people with severe epilepsy

Written by | 11 Feb 2024

The National Association of Epilepsy Centers (NAEC) has developed updated guidelines that outline the comprehensive services and resources epilepsy centers should provide to improve quality of care for… read more.

Investigative epilepsy drug shows significant efficacy

Written by | 13 Oct 2023

Among patients with treatment resistant epilepsy, the investigative drug XEN1101 has reduced seizure frequency by over 50%. And in some patients it stops them completely. Researchers reported these… read more.

Analyses of Valtoco (diazepam nasal spray) to be presented at Child Neurology Society meeting – Neurelis

Written by | 13 Oct 2023

Neurelis, Inc., announced additional findings from the post hoc analysis of the long-term phase III safety study of Valtoco (diazepam nasal spray) in a pediatric population, aged 6-17… read more.

Could fathers’ epilepsy treatment affect childhood development?

Written by | 8 Sep 2023

European medicines regulators are studying the potential risk of neurodevelopmental disorders (NDDs) in children conceived by fathers taking valproate, an epilepsy medicine. Preliminary data suggest a possible association… read more.

Health Canada approves Xcopri to treat partial offset seizures – Paladin Labs

Written by | 26 Jun 2023

SK Biopharmaceuticals said that Health Canada granted a Notice of Compliance for Xcopri (ingredient: cenobamate), its epilepsy drug, approving its application for marketing authorization in Canada. Paladin Labs,… read more.

Drug-resistant epilepsy responds to combination of diet and standard drugs

Written by | 20 Jan 2023

Use of a modified Atkins diet high in fat and low in carbohydrates plus standard medication appears to reduce seizures in patients with drug-resistant epilepsy, researchers reported on… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.